Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events : A Secondary Analysis of the PEGASUS-TIMI 54 Trial

• Authors: BONACA Marc P.; BHATT Deepak L.; OPHUIS Ton Oude; STEG Gabriel; STOREY Robert; COHEN Marc; KUDER Julia; IM Kyungan; MAGNANI Giulia; BUDAJ Andrzej; THEROUX Pierre; HAMM Christian; ŠPINAR Jindřich; KISS Robert G.; DALBY Anthony J.; MEDINA Felix A.; KONTNY Frederic; AYLWARD Philip E.; JENSEN Eca C.; HELD Peter; BRAUNWALD Eugene; SABATINE marc S.
• Year of publication: 2016
• Type: Article in Periodical
• Magazine / Source: JAMA Cardiology
• MU Faculty or unit: Faculty of Medicine
• web: https://jamanetwork.com/journals/jamacardiology/fullarticle/2528235
• Doi: https://doi.org/10.1001/jamacardio.2016.1017
• Field: Cardiovascular diseases incl. cardiosurgery
• Keywords: Ticagrelor; DUAL ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; CLOPIDOGREL; ASPIRIN
• Description: In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death,myocardial infarction, or stroke by 15%to 16%among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo.